InVisionFirst-Lung testing demonstrates excellent concordance with standard of care tissue profiling and enables more complete profiling of patients with advanced NSCLC
26% more actionable mutations found than standard of care tissue testing
Research Triangle Park, NC and Cambridge, UK, September 24, 2018 — Inivata, a leader in liquid biopsy today announces that results from its US multi-centre prospective validation study of its InVisionFirst-Lung liquid biopsy test will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).
The study recruited 264 patients with untreated advanced NSCLC at 41 US centres. 178 patients had tumor tissue available for molecular profiling of at least 1 gene and the remaining 86 patients without tissue were included to compare ctDNA profiles obtained from patients with and without tissue for profiling. Tissue-based NGS testing was performed for all patients where sufficient tissue was available.
Key results included:
Dr Ramaswamy Govindan said, “In this large-scale study, the InVisionFirst-Lung test had excellent concordance with tissue profiling and superior sensitivity and specificity. Importantly, using InVisionFirst-Lung led to the detection of 26% more actionable mutations than standard of care tissue testing, which relies on a painful, invasive procedure and can fail to provide sufficient tissue for analysis.”
Clive Morris, Chief Executive Officer at Inivata, said, “These data provide strong clinical validation for InVisionFirst-Lung and highlight its potential as a powerful means to aid treatment decisions for patients with advanced NSCLC. Importantly, the prospective clinical evaluation in unprofiled lung cancer patients characterises the performance of the test in the real-world setting facing clinicians and represents the gold standard validation of the performance of such tests.”
Read more here.